相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activation of Peroxisome Proliferator-Activated Receptor δ Inhibits Human Macrophage Foam Cell Formation and the Inflammatory Response Induced by Very Low-Density Lipoprotein
Lazar A. Bojic et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Lipid Effects of Peroxisome Proliferator-Activated Receptor-δ Agonist GW501516 in Subjects With Low High-Density Lipoprotein Cholesterol Characteristics of Metabolic Syndrome
Eric J. Olson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
Yun-Jung Choi et al.
ATHEROSCLEROSIS (2012)
The antiplatelet activity of magnolol is mediated by PPAR-β/γ
Ching-Yu Shih et al.
BIOCHEMICAL PHARMACOLOGY (2012)
No Evidence of QT Prolongation With Supratherapeutic Doses of Aleglitazar
Stefan Sturm et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2012)
The Role of Peroxisome Proliferator-Activated Receptors in Colorectal Cancer
Joo-In Park et al.
PPAR RESEARCH (2012)
PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells
David Alvarez-Guardia et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2011)
Activation of Peroxisome Proliferator-Activated Receptor-β/-δ (PPAR-β/-δ) Ameliorates Insulin Signaling and Reduces SOCS3 Levels by Inhibiting STAT3 in Interleuldn-6 Stimulated Adipocytes
Lucia Serrano-Marco et al.
DIABETES (2011)
Role of Lipid Peroxidation and PPAR-δ in Amplifying Glucose-Stimulated Insulin Secretion
Guy Cohen et al.
DIABETES (2011)
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice
A. Maida et al.
DIABETOLOGIA (2011)
Aleglitazar, a balanced PPAR alpha/gamma agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin
Adam J. Foley-Comer et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Inhibitory Effect of α-Lipoic Acid on Platelet Aggregation Is Mediated by PPARs
Tz-Chong Chou et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2011)
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants
Goodarz Danaei et al.
LANCET (2011)
Therapeutic applications of compounds in the Magnolia family
Young-Jung Lee et al.
PHARMACOLOGY & THERAPEUTICS (2011)
The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases
Sandeep Tyagi et al.
JOURNAL OF ADVANCED PHARMACEUTICAL TECHNOLOGY & RESEARCH (2011)
Non-genomic effects of PPARγ ligands: inhibition of GPVI-stimulated platelet activation
L. A. Moraes et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels
Akadiri Yessoufou et al.
SWISS MEDICAL WEEKLY (2010)
The Nuclear Hormone Receptor PPAR gamma as a Therapeutic Target in Major Diseases
Martina Victoria Schmidt et al.
THESCIENTIFICWORLDJOURNAL (2010)
Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome
Teresa Coll et al.
Current Molecular Pharmacology (2010)
Metabolic syndrome and risk of cancer mortality in men
Jason R. Jaggers et al.
EUROPEAN JOURNAL OF CANCER (2009)
Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
Robert R. Henry et al.
LANCET (2009)
Fat and beyond: The diverse biology of PPAR gamma
Peter Tontonoz et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2008)
Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus -: An effect probably mediated by direct platelet PPARγ activation
M. P. Khanolkar et al.
ATHEROSCLEROSIS (2008)
Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone
Voahanginirina Randriamboavonjy et al.
CIRCULATION (2008)
Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor γ in cardiac fibrosis
Evren Caglayan et al.
DIABETES (2008)
Inflammatory Pathways Are Activated during Cardiomyocyte Hypertrophy and Attenuated by Peroxisome Proliferator-activated Receptors PPARα and PPARδ
Pascal J. H. Smeets et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Identification and characterization of a selective peroxisome proliferator-activated receptor β/δ (NR1C2) antagonist
Barry G. Shearer et al.
MOLECULAR ENDOCRINOLOGY (2008)
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
Justin I. Odegaard et al.
NATURE (2007)
Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones
Andrea L. Hevener et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors
Liliane Michalik et al.
PHARMACOLOGICAL REVIEWS (2006)
The metabolic syndrome - A high-risk state for cancer?
Stephanie Cowey et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
BCL-6:: a possible missing link for anti-inflammatory PPAR-δ signalling in pancreatic beta cells
I. Kharroubi et al.
DIABETOLOGIA (2006)
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial
H. C. Gerstein et al.
LANCET (2006)
PPARδ modulates lipopolysaccharide-induced TNFα inflammation signaling in cultured cardiomyocytes
Guoliang Ding et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2006)
From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions
JN Feige et al.
PROGRESS IN LIPID RESEARCH (2006)
Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes
AH Xiang et al.
DIABETES (2006)
Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARβ
Ferhana Y. Ali et al.
FASEB JOURNAL (2006)
The PPARδ agonist GW0742X reduces atherosclerosis in LDLR-/- mice
TL Graham et al.
ATHEROSCLEROSIS (2005)
Functional interaction of protein kinase Cα with the tyrosine kinases Syk and Src in human platelets
G Pula et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
An overview on biological mechanisms of PPARs
BP Kota et al.
PHARMACOLOGICAL RESEARCH (2005)
Regulated membrane trafficking of the insulin-responsive glucose transporter 4 in adipocytes
RT Watson et al.
ENDOCRINE REVIEWS (2004)
Peroxisome proliferator-activated receptor α agonists increase nitric oxide synthase expression in vascular endothelial cells
K Goya et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: Effects on lipid homeostasis, inflammation, and atherosclerosis
M Ricote et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Expression and functional activity of PPARγ in pancreatic β cells
HJ Welters et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Platelet adhesion signalling and the regulation of thrombus formation
JM Gibbins
JOURNAL OF CELL SCIENCE (2004)
The metabolic syndrome: prevalence in worldwide populations
AJ Cameron et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2004)
Regulation of muscle fiber type and running endurance by PPARδ
YX Wang et al.
PLOS BIOLOGY (2004)
Peroxisome proliferator-activated receptors and atherogenesis - Regulators of gene expression in vascular cells
N Marx et al.
CIRCULATION RESEARCH (2004)
Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle
WM He et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome
T Tanaka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Phenolics with PPAR-γ ligand-binding activity obtained from licorice (Glycyrrhiza uralensis roots) and ameliorative effects of glycyrin on genetically diabetic KK-Ay mice
M Kuroda et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Muscle-specific Pparg deletion causes insulin resistance
AL Hevener et al.
NATURE MEDICINE (2003)
The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells
U Dressel et al.
MOLECULAR ENDOCRINOLOGY (2003)
Transcriptional repression of atherogenic inflammation:: Modulation by PPARδ
CH Lee et al.
SCIENCE (2003)
Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity
SM Rangwala et al.
DEVELOPMENTAL CELL (2003)
Peroxisome proliferator-activated receptor δ controls muscle development and oxydative capability
S Luquet et al.
FASEB JOURNAL (2003)
Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis
ST Yu et al.
CURRENT MOLECULAR MEDICINE (2003)
Peroxisome proliferator-activated receptor (PPAR)-α activation prevents diabetes in OLETF rats -: Comparison with PPAR-γ activation
EH Koh et al.
DIABETES (2003)
The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-δ to induce apoptosis in colorectal cancer cells
I Shureiqi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Direct demonstration of involvement of protein kinase Cα in the Ca2+-induced platelet aggregation
A Tabuchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Platelet-collagen interaction: is GPVI the central receptor?
B Nieswandt et al.
BLOOD (2003)
Diagnosis, prevention, and intervention for the metabolic syndrome
CL Scott
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors
CH Lee et al.
ENDOCRINOLOGY (2003)
The metabolic syndrome:: Peroxisome proliferator-activated receptor γ and its therapeutic modulation
M Gurnell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ) -: Synthesis and biological activity
ML Sznaidman et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Insulin resistance and cardiovascular events with low HDL cholesterol - The Veterans Affairs HDL Intervention Trial (VA-HIT)
SJ Robins et al.
DIABETES CARE (2003)
Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity
YX Wang et al.
CELL (2003)
Treatment for patients with the metabolic syndrome
HN Ginsberg
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation
D Bishop-Bailey et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2003)
The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones
P Arner
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2003)
Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice
BL Knight et al.
JOURNAL OF LIPID RESEARCH (2003)
Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E
YQ Huo et al.
NATURE MEDICINE (2003)
Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice
H Duez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Emerging roles of PPARs in inflammation and immunity
RA Daynes et al.
NATURE REVIEWS IMMUNOLOGY (2002)
The CYP4A Isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands
LA Cowart et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The role of PPARs in atherosclerosis
C Duval et al.
TRENDS IN MOLECULAR MEDICINE (2002)
Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women
TA Buchanan et al.
DIABETES (2002)
Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial
JL Chiasson et al.
LANCET (2002)
Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management
JA Beckman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Cb1, IRS-1 and IRS-2 mediate effects of rosiglitazone on PI3K, PKC-λ, and glucose transport in 3T3/L1 adipocytes
ML Standaert et al.
ENDOCRINOLOGY (2002)
Two new furanoditerpenes from Saururus chinenesis and their effects on the activation of peroxisome proliferator-activated receptor γ
BY Hwang et al.
JOURNAL OF NATURAL PRODUCTS (2002)
The role of PPARs in the transcriptional control of cellular processes
YF Guan et al.
DRUG NEWS & PERSPECTIVES (2002)
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
WC Knowler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer
Y Barak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Metabolic and additional vascular effects of thiazolidinediones
FMAC Martens et al.
DRUGS (2002)
The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes
AB Mayerson et al.
DIABETES (2002)
Insulin signalling and the regulation of glucose and lipid metabolism
AR Saltiel et al.
NATURE (2001)
Peroxisome proliferator-activated receptor-γ activity is associated with renal microvasculature
YF Guan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2001)
Nuclear receptors and lipid physiology: Opening the X-files
A Chawla et al.
SCIENCE (2001)
Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats
D Kramer et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2001)
Peroxisome proliferator-activated receptor (PPAR) modulators: Diabetes and beyond
AB Jones
MEDICINAL RESEARCH REVIEWS (2001)
PPARγ:: a nuclear regulator of metabolism, differentiation, and cell growth
ED Rosen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
T Yamauchi et al.
NATURE MEDICINE (2001)
Peroxisome proliferator-activated receptor-γ:: from adipogenesis to carcinogenesis
L Fajas et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2001)
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
YF Guan et al.
KIDNEY INTERNATIONAL (2001)
Peroxisome proliferator-activated receptors in inflammation control
P Delerive et al.
JOURNAL OF ENDOCRINOLOGY (2001)
Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-γ by flavonoids in mouse macrophages
YC Liang et al.
FEBS LETTERS (2001)
A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport
WR Oliver et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity
J Berger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Cardiovascular morbidity and mortality associated with the metabolic syndrome
B Isomaa et al.
DIABETES CARE (2001)
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
G Chinetti et al.
NATURE MEDICINE (2001)
Thiazolidinediones (PPAR gamma agonists) but not PPAR alpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes
U Smith et al.
FASEB JOURNAL (2001)
Emerging concepts In metabolic abnormalities associated with coronary artery disease
J Plutzky
CURRENT OPINION IN CARDIOLOGY (2000)
Docosahexaenoic acid, a peroxisome proliferator-activated receptor-α ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase
QN Diep et al.
HYPERTENSION (2000)
Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis
BP Neve et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Obesity and insulin resistance
BB Kahn et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ)
JM Peters et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Roles of PPARs in health and disease
S Kersten et al.
NATURE (2000)
CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors
G Chinetti et al.
CIRCULATION (2000)
Activation of PPARδ alters lipid metabolism in db/db mice
MD Leibowitz et al.
FEBS LETTERS (2000)
Expression and function of PPARγ in rat and human vascular smooth muscle cells
RE Law et al.
CIRCULATION (2000)
PPARδ functions as a prostacyclin receptor in blastocyst implantation
H Lim et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2000)
Peroxisome proliferator-activated receptors in the cardiovascular system
D Bishop-Bailey
BRITISH JOURNAL OF PHARMACOLOGY (2000)
A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation
HM Wright et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
